These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
197 related items for PubMed ID: 21041920
1. Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon. Cournil A, Coudray M, Kouanfack C, Essomba CN, Tonfack CA, Biwolé-Sida M, Delaporte E, Bork K, Laurent C. Antivir Ther; 2010; 15(7):1039-43. PubMed ID: 21041920 [Abstract] [Full Text] [Related]
2. Unrecognized near-fatal hyperlactatemia in an HIV-infected infant exposed to nucleoside reverse transcriptase inhibitors. Koh MT. Int J Infect Dis; 2007 Jan; 11(1):85-6. PubMed ID: 16581278 [No Abstract] [Full Text] [Related]
5. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study. Anekthananon T, Ratanasuwan W, Techasathit W, Sonjai A, Suwanagool S. J Med Assoc Thai; 2004 Jul; 87(7):760-7. PubMed ID: 15521230 [Abstract] [Full Text] [Related]
6. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients. Tin EE, Bowonwatanuwong C, Desakorn V, Wilairatana P, Krudsood S, Pitisuttithum P. Southeast Asian J Trop Med Public Health; 2005 Mar; 36(2):362-9. PubMed ID: 15916042 [Abstract] [Full Text] [Related]
9. Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda. van Griensven J, Zachariah R, Rasschaert F, Mugabo J, Atté EF, Reid T. Trans R Soc Trop Med Hyg; 2010 Feb; 104(2):148-53. PubMed ID: 19732926 [Abstract] [Full Text] [Related]
13. [Clinical safety of a generic fixed-dose combination of stavudine/lamivudine/névirapine (Triomune). Study of 297 cases in Togo]. Mouhari-Touré A, Saka B, Kombat K, Tchangaï-Walla K, Pitche P. Bull Soc Pathol Exot; 2008 Dec; 101(5):404-6. PubMed ID: 19192611 [Abstract] [Full Text] [Related]
14. [Evaluation of antiretroviral therapy in HIV-infected adults in the Department of Haematology, University Hospital of Brazzavllle, Congo]. Dokekias AE, Galiba FO, Bokilo AD, Ntsimba P, Nsitou MB, Malanda F, Basseila GB. Bull Soc Pathol Exot; 2008 Apr; 101(2):109-12. PubMed ID: 18543703 [Abstract] [Full Text] [Related]
15. Developing countries need better antiretroviral drugs. Mykén N, Sundbeck B, Mpumilwa G, Andersson R. J Int Assoc Physicians AIDS Care (Chic); 2009 Apr; 8(1):23-4. PubMed ID: 19171914 [No Abstract] [Full Text] [Related]
16. Demographic, socio-economic, behavioral and clinical factors predicting virologic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand. Tsuchiya N, Pathipvanich P, Yasuda T, Mukoyama Y, Rojanawiwat A, Matsubayashi T, Saeng-aroon S, Auwanit W, Matsuyama A, Sawanpanyalert P, Ariyoshi K. Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):71-82. PubMed ID: 19323037 [Abstract] [Full Text] [Related]
20. Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon. Bourgeois A, Laurent C, Mougnutou R, Nkoué N, Lactuock B, Ciaffi L, Liégeois F, Andrieux-Meyer I, Zekeng L, Calmy A, Mpoudi-Ngolé E, Delaporte E. Antivir Ther; 2005 Jan; 10(2):335-41. PubMed ID: 15865228 [Abstract] [Full Text] [Related] Page: [Next] [New Search]